PRL and neuroblastoma: Due to concerns regarding the potential for dopamine to induce an increase in prolactin levels, which can theoretically inhibit T-cell function, dopamine is not the preferred vasopressor for use in patients with high-risk neuroblastoma receiving immunotherapy.